Premium
Cutaneous adverse‐events in patients treated with Ibrutinib
Author(s) -
Pileri Alessandro,
Guglielmo Alba,
Agostinelli Claudio,
Evangelista Valeria,
Bertuzzi Clara,
Alessandrini Aurora,
Bruni Francesca,
Starace Michela,
Massi Alice,
Broccoli Alessandro,
Patrizi Annalisa,
Zinzani Pier Luigi,
Piraccini Bianca Maria
Publication year - 2020
Publication title -
dermatologic therapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.595
H-Index - 68
eISSN - 1529-8019
pISSN - 1396-0296
DOI - 10.1111/dth.14190
Subject(s) - ibrutinib , medicine , adverse effect , dermatology , rash , concomitant , impetigo , leukemia , chronic lymphocytic leukemia
Ibrutinib is a Burton tyrosine kinase inhibitor (BTKi) approved for the treatment of several hematologic malignancies. Analyze skin adverse events (SAE). All the patients treated with Ibrutinib featuring cutaneous adverse events were selected. Twenty five patients were retrieved with a median interval between Ibrutinib start and SAE time of onset of 120 days. Most common SAE observed involved hairs and nails. Eczematous reaction and leucocytoclastic vasculitis were also detected. One patient had a long‐history Ibrutinib treatment and experienced numerous cutaneous adverse events. Infective disease such as superficial mycosis and impetigo were rarely present in our series. Despite the development of cutaneous SAE, all the patients continued their concomitant drugs without the onset of any further SAE. Our data suggest Ibrutinib‐associated rash should be distinguished in early and late events and a careful dermatologic management of patients should be scheduled.